Heineken warns that the popularity of weight-loss drugs in Britain could reduce sales of beer and cider in pubs and bars. Citing a presentation shared with hospitality customers, the brewer says medicines in the GLP-1 family—including products such as Wegovy and Ozempic—can reduce the desire to drink alcohol.
Across the coverage, the key practical effect described is that customers may feel fuller and have “fewer serves” of pints, leading to lower volume sales for beer-focused outlets. Reuters reports the company has urged pubs and bars to adapt to the change, while The Guardian frames the same warning around the broader “boom” in drug use and its potential impact on drinking habits.
The Economic Times repeats the central concern that Heineken’s outlook for beer sales is affected by changing consumer behaviour linked to weight-loss drugs. All sources treat the warning as an unusual acknowledgement by a major alcohol producer that GLP-1 medications could pose a threat to alcohol sales in the UK hospitality sector.
